Dow hits record highs & S&P 500 healthcare gains. Discover key stock movers, Trump-era pharma tariffs capped, & major healthcare earnings updates.

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

After a 20% stock plunge, Denmark's prized drugmaker triggers fears over jobs, confidence, and consumer spending.

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low. Denmark’s confidence index fell to -17.2 this month, according to official ...

The health sector faces a range of global challenges and developments, including Indian tax proposals, trade impacts on Brazilian chicken exports, and activist investment in Gerresheimer. Other key ...

Novo issues global hiring freeze for non-critical jobs; RFK, Jr. feuds with American Academy of Pediatrics; Why direct-to-consumer sales are unlikely to significantly lower drug costs.

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...